- Home
- OVID vs TCRX Comparison
OVID vs TCRX Comparison
Compare OVID & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- TCRX
- Stock Information
- Founded
- OVID 2014
- TCRX 2018
- Country
- OVID United States
- TCRX United States
- Employees
- OVID N/A
- TCRX N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- TCRX Health Care
- Exchange
- OVID Nasdaq
- TCRX Nasdaq
- Market Cap
- OVID 117.3M
- TCRX 140.7M
- IPO Year
- OVID 2017
- TCRX 2021
- Fundamental
- Price
- OVID $1.32
- TCRX $1.09
- Analyst Decision
- OVID Strong Buy
- TCRX Strong Buy
- Analyst Count
- OVID 4
- TCRX 6
- Target Price
- OVID $3.13
- TCRX $8.80
- AVG Volume (30 Days)
- OVID 1.7M
- TCRX 880.8K
- Earning Date
- OVID 11-13-2025
- TCRX 11-07-2025
- Dividend Yield
- OVID N/A
- TCRX N/A
- EPS Growth
- OVID N/A
- TCRX N/A
- EPS
- OVID N/A
- TCRX N/A
- Revenue
- OVID $6,651,000.00
- TCRX $6,961,000.00
- Revenue This Year
- OVID $1,081.80
- TCRX $255.18
- Revenue Next Year
- OVID N/A
- TCRX N/A
- P/E Ratio
- OVID N/A
- TCRX N/A
- Revenue Growth
- OVID 1070.95
- TCRX N/A
- 52 Week Low
- OVID $0.24
- TCRX $1.02
- 52 Week High
- OVID $2.01
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- OVID 41.52
- TCRX 25.12
- Support Level
- OVID $1.27
- TCRX $1.08
- Resistance Level
- OVID $1.44
- TCRX $1.17
- Average True Range (ATR)
- OVID 0.10
- TCRX 0.17
- MACD
- OVID -0.04
- TCRX -0.14
- Stochastic Oscillator
- OVID 14.29
- TCRX 0.68
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.